SHAPING FRANCE AS ONE OF THE MOST COMPETITIVE AND INNOVATIVE HEALTHTECH HUBS
A FUTURE EUROPEAN LEADER IN HEALTHTECH

Ranked as a leader in terms of access to health care by the OECD, France’s health sector has demonstrated its resilience during the Covid crisis.

In order to become a new global hub for health technologies and the first European country for the production of new drugs, France needs to welcome more foreign investor.

€90 Bn turnover (French Health Industry Federation)
3rd largest export sector (worth €34 Bn)
€6.7 Bn annual investment in R&D
30,000 public researchers

A unique social protection system guaranteeing 67M people an easy access to healthcare and drugs.
The French universal health insurance covers 76.8% of health expenditures for people working or living in France
French public expenditures for health care amount to €200Bn
THE SECOND LARGEST PHARMACEUTICAL MARKET IN EUROPE

The world’s 5th largest market for drugs for human use

€60 bn generated by the French pharmaceutical companies in 2019 (Leem, 2020)
3,100 pharmaceutical companies employing 455,000 people

720 Biotech companies (oncology is their primary therapeutic focus)
886 MedTech and Diagnostic (panorama France Biotech 2019)
60 new biotech companies created every year (Féfis)

Over 22,000 pharmacies
An average of €488 in pharmaceutical spending per capita in France in 2018 (Leem, 2019)
A COLLABORATIVE INNOVATION ECOSYSTEM

4 research centers listed in the Top 25 World’s Most Innovative Research Institutions 2019
(Reuters)

Inserm
2nd leading medical research institute in the world (Scimago, 2018)
1st country in Europe in terms of patents filed in biotechnology and pharmaceuticals (EPO, 2018)

73 universities
(Université Paris-Saclay ranks 14 in Shanghai’s Academic ranking of World Universities 2020)

13 Nobel prizes in Medecine (French Healthcare 2019)

52% of the healthtech companies created in France are spinout of public or academic research institutions (France Biotech 2019)

800 M€ R&D tax credit per year for the health industry in France

1st European country in numbers of clinical trials (Panorama France Healthtech 2019)
DEVELOPING BIOPRODUCTION
BY PROMOTING DISRUPTIVE TECHNOLOGY

“The production of innovative biological therapies is a major competitive stake but is also essential to guarantee better patient access to tomorrow’s innovations and to guarantee our health independence.” (Rapport Conseil National de l’Industrie, 2019)

32 bioproduction sites in France (with 3 international companies) representing 8,463 jobs

France aims to:

- attract and develop disruptive technologies
- lower its bioproduction cost
- create a network of start-ups and SMEs
- strengthen its training offer in new technologies

6 action plans (including bioproduction) led by the CSF-ITS (Strategic Committee for the Health Industries and Technologies Sector) among which:

- Artificial Intelligence and Health
- Antibioresistance
- Employment and training
DIGITAL HEALTH IS A GOVERNMENT PRIORITY

A € 3Bn market with a potential of up to 16 to 22 Bn per year (The Montaigne Institute, 2019) driven by:

- **the aging of its population.** € 11 Bn for the long-term care for the elderly (+ 2% per year in recent years);
- **the development of chronic diseases**
- **the need to optimize the patient journey.** Transporting patients (€ 5 Bn/year) and nursing care in urban areas (€ 8 Bn/year) are both increasing by around 4%/year while consumption of hospital resources (€ 72 Bn/year) is growing by 2%/year. *(rapport Potier 2019)*

THE FRENCH GOVERNMENT LAUNCHED SEVERAL INITIATIVES:

<table>
<thead>
<tr>
<th>Health Data Hub</th>
<th>Ma Santé 2022</th>
<th>PIA4</th>
<th>“Engagé pour la e-santé”</th>
</tr>
</thead>
<tbody>
<tr>
<td>simplified access to health data for all professionals and research teams</td>
<td>fostering the transition to digital health, with tools such as shared medical records</td>
<td>(Investments for the Future Programme) specific investments in digital health</td>
<td>a agreement chart signed by 235 healthtech companies</td>
</tr>
</tbody>
</table>

Over **200** Digital health start-ups employing **30,000** people in France *(French Healthcare 2019)*
A STRATEGY TO BOOST THE COMPETITIVENESS OF COMPANIES

SECURE THE VALUE CHAIN AND ATTRACT NEW INVESTMENTS


BOOST INVESTMENTS IN INDUSTRY 4.0

September 2020:
€240 M for industry 4.0, including €40m in 2020
Industrial projects carried out by Small and Mid-Size Companies
A new support mechanism to finance up to 40% of eligible equipment (robotic equipment, data collecting sensors, augmented reality and virtual reality equipment, software or equipment using artificial intelligence) for call for projects in 2020, 2021 and 2022

SUPPORT PRIVATE AND PUBLIC RESEARCH

€25Bn - For additional public investment in French research system over the next 10 years, including €5Bn in health sciences
€300M - To enhance bridges between private and public research by creating temporary (12 to 24 months) of private R&D jobs for private sector researchers in public laboratories 80% of the salary covered by the government
An attractive and stable Research Tax Credit (30% of annual R&D expenditures up to €100 M per company) ranking France first among OECD countries for R&D funding (2019)

ENCOURAGE THE DECARBONATION OF INDUSTRY

A budgetary envelope of 1,2Md€ including €200 M in 2020 – a new fund aimed at the decarbonation of industry
Grant for industrial companies to purchase equipment to reduce CO2 emissions or improve energy efficiency.
List of eligible expenditures here
Maximum grant (depending on the type of equipment): up to 30% of the eligible expenses for large companies; up to 40% for mid-size companies; up to 50% for SMEs
A STRATEGY TO BOOST THE COMPETITIVENESS OF COMPANIES

ACCELERATE MARKET ACCESS FOR INNOVATIVE PRODUCTS

September 2020:
Launch of GIO, “Guichet Innovation & Orientation” by the French National Agency for Health Products (ANSM), a new portal and support service to guide innovative companies through French legal procedures, from R&D to marketing.
Starting in 2021, a major simplification of the French early access scheme (Temporary Authorization Process - ATU) will fast-track patient access to innovations and give more predictability to companies.

MODERNIZE HEALTHCARE INFRASTRUCTURE

€6Bn - For the transformation, renovation, equipment and digitization of medico-social establishments.
The restructuring the healthcare offer
The modernization of digital tools in healthcare
REGULATORY FRAMEWORK: A REGULAR AND CONSTRUCTIVE DIALOGUE BETWEEN THE GOVERNMENT AND THE HEALTHCARE INDUSTRIES

<table>
<thead>
<tr>
<th>STRATEGIC COUNCIL FOR THE HEALTHCARE INDUSTRIES (CSIS)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Next CSIS: July 2021</strong></td>
</tr>
<tr>
<td>A unique biennial forum created in 2004 which brings together public decision-makers and leaders of French &amp; international companies</td>
</tr>
<tr>
<td>Common work agenda – Reciprocal commitments – New measures on organizational issues in the healthcare industry</td>
</tr>
<tr>
<td>8th CSIS held in July 2018: 48 new measures, 85% of which already effective with tangible results: Health Data Hub – Fast track for clinical trials – Towards more competitiveness and predictability for international companies choosing France</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MULTI-YEAR REGULATORY FRAMEWORK AGREEMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Principle of Government/Industry contractual relationship – a French specificity which is appreciated by healthcare companies</td>
</tr>
<tr>
<td>Shaped by pluriannual reference frameworks for the pricing and regulation of healthcare products in France</td>
</tr>
<tr>
<td>Established between the Pricing Committee (CEPS) and key industry representative bodies (LEEM for pharma / SNITEM for MTD)</td>
</tr>
<tr>
<td>Pharma: new agreement under negotiation – exp. by the end of 2020</td>
</tr>
</tbody>
</table>